Emily Suzanne Brouwer

Emily Suzanne Brouwer

Auto-generated profile, based on publicly available information

Emily Suzanne Brouwer

Department of Epidemiology, Gillings School of Global Public Health †Department of Medicine, Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC ‡College of Pharmacy, Institute for Pharmaceutical Outcomes and Policy, University of Kentucky, Lexington, KY §Department of Medicine, Division of Cardiology, University of North Carolina, Chapel Hill, NC

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SSSujit Suchindran
Sujit Suchindran
EBEmily S. Brouwer
Emily S. Brouwer
ARAnnelies Van Rie
Annelies Van Rie
Tuberculosis (TB) is an important cause of human suffering and death. Human immunodeficiency virus (HIV), multi-drug resistant TB (MDR-TB), and extensive drug resistant tuberculosis (XDR-TB) have emerged as threats to TB control. The association between MDR-TB and HIV infection has not yet been fully investigated. We conducted a systematic review and meta-analysis to summarize the evidence on the association between HIV infection and MDR-TB. Original studies providing Mycobacterium tuberculosis resistance data stratified by HIV status were identified using MEDLINE and ISI Web of Science. Crude MDR-TB prevalence ratios were calculated and analyzed by type of TB (primary or acquired), region and study period. Heterogeneity across studies was assessed, and pooled prevalence ratios were generated if appropriate. No clear association was found between MDR-TB and HIV infection across time and geographic locations. MDR-TB prevalence ratios in the 32 eligible studies, comparing MDR-TB prevalence by HIV status, ranged from 0.21 to 41.45. Assessment by geographical region or study period did not reveal noticeable patterns. The summary prevalence ratios for acquired and primary MDR-TB were 1.17 (95% CI 0.86, 1.6) and 2.72 (95% CI 2.03, 3.66), respectively. Studies eligible for review were few considering the size of the epidemics. Most studies were not adjusted for confounders and the heterogeneity across studies precluded the calculation of a meaningful overall summary measure. We could not demonstrate an overall association between MDR-TB and HIV or acquired MDR-TB and HIV, but our results suggest that HIV infection is associated with primary MDR-TB. Future well-designed studies and surveillance in all regions of the world are needed to better clarify the relationship between HIV infection and MDR-TB.

1 May 2014 in Epidemiology
Verified
Journal Article
Closed access
EBEmily S. Brouwer
Emily S. Brouwer
SNSonia Napravnik
Sonia Napravnik
JEJoseph J. Jr. Eron
Joseph J. Jr. Eron
BSBrant Stalzer
Brant Stalzer
MFMichelle Floris-Moore
Michelle Floris-Moore
TSTil Stürmer
Til Stürmer
Background: Cohort studies have demonstrated greater risk of myocardial infarction (MI) associated with specific antiretroviral use, while meta-analyses of randomized controlled trials (RCTs) have not. These differences may be due to inherent biases in the observational study design or to the limited duration of randomized trials. We conducted a new-user, active-comparator cohort study emulating an RCT comparing the initiation of several antiretrovirals as part of combination antiretroviral therapy (cART) and MI. Methods: We included North Carolina (NC) Medicaid beneficiaries infected with human immunodeficiency virus between 2002 and 2008 who were previously untreated with cART. We compared hazard ratios (HRs) and 95% confidence intervals (CIs) of MI between abacavir and tenofovir recipients, and lopinavir-ritonavir or atazanavir recipients and nonnucleoside reverse transcriptase inhibitor (NNRTI) recipients. We adjusted for confounding through inverse probability weighting methods. Results: There were 3481 NC Medicaid new cART recipients who contributed 6399 person-years and experienced 38 MI events. Receiving abacavir compared with tenofovir as part of cART was associated with an increased rate of MI (unadjusted HR = 2.70 [95% CI = 1.24–5.91]; adjusted HR = 2.05 [0.72–5.86]). Point estimates also suggest a relationship between receipt of atazanavir or lopinavir-ritonavir compared with an NNRTI and MI, although estimates were imprecise. Conclusions: We found an increased rate of MI among patients initiating abacavir compared with tenofovir, although the association was decreased after confounding adjustment. Without a very large prospective comparative clinical trial, a much larger observational study of patients initiating cART would be needed to better define this apparent association.

26 February 2013 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
SWSuzanne L. West
Suzanne L. West
LSLinda B. Squiers
Linda B. Squiers
LMLauren McCormack
Lauren McCormack
BSBrian Southwell
Brian Southwell
EBEmily S. Brouwer
Emily S. Brouwer
HSHelen W. Sullivan
Helen W. Sullivan

16 January 2012 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
EBEmily S. Brouwer
Emily S. Brouwer
SWSuzanne L. West
Suzanne L. West
MKMarianne Kluckman
Marianne Kluckman
DWDennis Wallace
Dennis Wallace
AMAndrew L. Masica
Andrew L. Masica
NFNeil S. Fleming
Neil S. Fleming

1 November 2006 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
RHRichard A. Hansen
Richard A. Hansen
MRMary T. Roth
Mary T. Roth
EBEmily S. Brouwer
Emily S. Brouwer
SHSusan Herndon
Susan Herndon
DCDale B. Christensen
Dale B. Christensen

24 February 2013 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
AMAndrew L. Masica
Andrew L. Masica
EEEdward Ewen
Edward Ewen
YDYahya A. Daoud
Yahya A. Daoud
DCDunlei Cheng
Dunlei Cheng
NFNora Franceschini
Nora Franceschini
SWSuzanne L. West
Suzanne L. West